MetaCap

Editas Medicine (EDIT) vs Ocugen (OCGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Editas Medicine (EDIT) has outperformed Ocugen (OCGN) over the past year, losing 32.2% versus a loss of 33.8%. Over five years, OCGN leads with a -88.1% price change compared with -94.9% for EDIT. Ocugen is the larger company by market cap ($260.6 million vs $253.1 million), about 1.0 times the size, while Editas Medicine is growing revenue faster (+25.4% vs +8.8%).

Editas Medicine converts more of its revenue into profit, with a net margin of -395.0% versus -1537.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EDIT-32.23%OCGN-33.80%
+121%+37%-47%
Nov 21, 20251 yearNov 20, 2026
EDIT-95.36%OCGN-90.05%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EDIT versus OCGN key metrics
MetricEDITOCGN
Share price$1.64$0.7679
Market cap$253.12M$260.55M
1-day change-4.09%+4.79%
YTD return-20.00%-43.12%
1-year return-32.23%-33.80%
5-year return-94.93%-88.09%
EPS (TTM)$-0.54$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$40.52M$4.41M
Revenue growth (YoY)+25.39%+8.83%
Net income (latest FY)$-160.06M$-67.85M
Operating margin-394.89%-1425.70%
Net margin-395.01%-1537.41%
52-week high$3.94$2.73
52-week low$1.63$0.691
Distance from 52-week high-58.38%-71.82%
Analyst consensusbuystrong_buy
Avg. price target upside+271.95%+1484.84%
Average volume2.63M7.34M
Shares outstanding154.34M339.31M
Employees87116
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Editas Medicine is more profitable, keeping -395.0 cents of every revenue dollar as net income versus -1537.4 cents for Ocugen.
  • Editas Medicine grew revenue faster in its latest fiscal year (+25.39% vs +8.83%).

About Editas Medicine

EDIT stock →

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees

About Ocugen

OCGN stock →

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees

EDIT vs OCGN FAQ

Which is bigger, Editas Medicine or Ocugen?

Ocugen (OCGN) is larger, with a market capitalization of $260.55M compared with $253.12M for Editas Medicine (EDIT).

Which stock has performed better over the past year, EDIT or OCGN?

EDIT returned -32.23% over the past 12 months, compared with -33.80% for OCGN (price return, excluding dividends). Past performance does not predict future results.

Are Editas Medicine and Ocugen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons